Deutsche Bank Aktiengesellschaft reiterated their buy rating on shares of GSK (LON:GSK – Free Report) in a report published on Friday, MarketBeat Ratings reports. Deutsche Bank Aktiengesellschaft currently has a GBX 1,950 ($24.74) target price on the stock.
Several other equities research analysts have also recently issued reports on the stock. Barclays reaffirmed an equal weight rating and set a GBX 1,725 ($21.88) target price on shares of GSK in a research note on Tuesday, May 7th. Citigroup reaffirmed a buy rating and set a GBX 2,100 ($26.64) price objective on shares of GSK in a research note on Monday, June 24th. JPMorgan Chase & Co. reissued an underweight rating on shares of GSK in a research note on Tuesday, June 18th. Shore Capital restated a buy rating on shares of GSK in a research report on Thursday. Finally, Jefferies Financial Group reaffirmed a buy rating and issued a GBX 2,100 ($26.64) price target on shares of GSK in a report on Thursday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company has an average rating of Moderate Buy and a consensus target price of GBX 1,791.25 ($22.72).
Get Our Latest Analysis on GSK
GSK Price Performance
GSK Cuts Dividend
The firm also recently announced a dividend, which will be paid on Thursday, July 11th. Shareholders of record on Thursday, May 16th will be paid a dividend of GBX 15 ($0.19) per share. The ex-dividend date is Thursday, May 16th. This represents a yield of 0.9%. GSK’s dividend payout ratio (DPR) is 5,504.59%.
Insider Buying and Selling at GSK
In other GSK news, insider Wendy Becker acquired 446 shares of the business’s stock in a transaction that occurred on Thursday, June 20th. The stock was purchased at an average cost of GBX 1,614 ($20.47) per share, with a total value of £7,198.44 ($9,131.60). Company insiders own 1.60% of the company’s stock.
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Further Reading
- Five stocks we like better than GSK
- How to Invest in Biotech Stocks
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- Compound Interest and Why It Matters When Investing
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- What Does Downgrade Mean in Investing?
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.